Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -3K | -4M | -6M | -7M | -9M |
| Operating Income | -9M | -7M | -11M | -11M | -14M |
| EBITDA | -9M | -7M | -11M | -11M | -13M |
| Net Income | -9M | -7M | -11M | -11M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.03
-4.63% today
1Y Change
-51.54%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Phio Pharmaceuticals Corp. (PHIO) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $1.03 and down 51.5% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -59.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -59.3%, free cash flow -12.3% with operating margin 0.0% and ROIC -43.8%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHIO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHIO Max Drawdown
-68.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHIO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$13.3M
-15.7% YoY
Free Cash Flow
-$11.9M
+2.8% YoY
Revenue Growth
+0.0%
EPS Growth
-59.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -3K | -4M | -6M | -7M | -9M |
| Operating Income | -9M | -7M | -11M | -11M | -14M |
| EBITDA | -9M | -7M | -11M | -11M | -13M |
| Net Income | -9M | -7M | -11M | -11M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 5M | 8M | 12M | 24M |
| Total Assets | 21M | 6M | 9M | 13M | 25M |
| Total Liabilities | 1M | 1M | 2M | 2M | 3M |
| Shareholder Equity | 20M | 5M | 8M | 11M | 22M |
| Total Debt | 0 | 0 | 35K | 170K | 295K |
| Net Debt | -21M | -5M | -8M | -12M | -24M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+2.2% YoY
Capital Expenditures
51K
+57.9% YoY
Free Cash Flow
12M
+2.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-66.6%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.